Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268

Synapse

Volumn 62, Issue 2, 2008, Pages 154-158

  Seeman, Philip ^a   Caruso, Carla ^b   Lasaga, Mercedes ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

D2 receptor; Dopamine agonist; Glutamate agonist; LY 354,740; LY 379,268; Psychosis; Schizophrenia

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; DOMPERIDONE; DOPAMINE 2 RECEPTOR; EGLUMETAD; GLUTAMATE RECEPTOR AGONIST; METABOTROPIC RECEPTOR AGONIST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOPAMINE RELEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HYPOPHYSIS CELL; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; RAT;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CRICETULUS; DOMPERIDONE; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; TRANSFECTION;

EID: 37549049717     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20482     Document Type: Article

References (25)

1. 1A agonist properties. Neuropsychopharmacology 31:1869-1879.
2. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. 2000. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenyl-acetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. J Neurochem 75:1147-1154.
3. Caruso C, Bottino MC, Pampillo M, Pisera D, Jaita B, Duvilanksi B, Seilicovich A, Lasaga M. 2004. Glutamate induces apoptosis in anterior pituitary cells through group ii metabotropic glutamate receptor activation. Endocrinology 145:4677-4684.
4. Cosi C, Carilla-Durand E, Assie MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A. 2006. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535:135-144.
5. Goff DC, Coyle JT. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.
6. Greenslade RG, Mitchell SN. 2004. Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology 47:1-8.
7. Johnson MP, Chamberlain M. 2002. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Neuropharmacology 43:799-808.
8. Jordan S, Chen R, Fernalld R, Johnson J, Regardie K, Kambayashi J, Tadori Y, Kitagawa H, Kikuchi T. 2006. In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors. Eur J Pharmacol 540:53-56.
9. 2 receptors - Implications for models of schizophrenia. Mol Psychiatry 7:837-844.
10. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry 48:627-640.
11. Longer receptor has a high-affinity state and inhibits adenylyl cyclase. Brain Res Mol Brain Res 77:281-284.
12. Pampillo M, Theas S, Duvilanski B, Seilicovich A, Lasaga M. 2002. Effect of ionotropic and metabotropic glutamate agonists and D-aspartate on prolactin release from anterior pituitary cells. Exp Clin Endocrinol Diabetes 110:138-144.
13. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102-1107.
14. Schoepp DD, Marek GJ. 2002. Preclinical pharmacology of mGlu2/3 receptor agonists: Novel agents for schizophrenia? Curr Drug Targets CNS Neurolog Disord 1:165-175.
15. Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Monn JA. 1998. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist. Naunyn Schmiedebergs Arch Pharmacol 358:175-180.
16. Schoepp DD, Jane DE, Monn JA. 1999. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476.
17. Seeman P. 2006. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 10:515-531.
18. Seeman P, Lasaga M. 2005. Dopamine agonist action of phencyclidine. Synapse 58:275-277.
19. 3H]spiperone depend on tissue concentration: Analysis and examples. J Neurochem 43:221-235.
20. 3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 49:209-215.
21. Seeman P, Ko F, Tallerico T. 2005. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877-883.
22. High dopamine receptors. Synapse 60:319-346.
23. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25.
24. Tuominen HJ, Tiihonen J, Wahlbeck K. 2005. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophr Res 72:225-234.
25. van Berckel BN, Kegeles LS, Waterhouse R, Guo N, Hwang DR, Huang Y, Narendran R, Van Heertum R, Laruelle M. 2006. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31:967-977.